Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

Sep. 15, 2021 1:03 PM ETBiomerica, Inc. (BMRA) StockEXAS, BMRA2 Comments
BOOX Research
20.33K Followers

Summary

  • Biomerica recently reported its fiscal 2021 Q4 results highlighted by key product updates supporting a positive long-term outlook.
  • The company's irritable bowel syndrome "IBS" diagnostic therapy technology platform continues to move towards an FDA approval representing a significant growth opportunity.
  • While the stock has been volatile, we believe upcoming catalysts can drive shares higher through 2022.
Doctors Appointment
Geber86/E+ via Getty Images

Biomerica, Inc. (NASDAQ:BMRA) develops and manufactures diagnostic products focusing on gastrointestinal diseases like irritable bowel syndrome “IBS” and other chronic inflammatory conditions. While the company has several products on the market, the real attraction is its Diagnostic Guided Therapy "DGT" platform known as "InFoods" currently in a

Add some conviction to your trading! We sort through +4,000 ETFs/CEFs along with +16,000 U.S. stocks/ADRs to find the best trade ideas. Click here for a two-week free trial and explore our content at the Conviction Dossier.

This article was written by

20.33K Followers
BOOX Research run by Dan Victor, CFA specializes in covering small-caps and under-the-radar ideas. Dan brings more than 15 years of experience in financial services across multiple roles in research, investment management, and trading. Dan is also the winner of Seeking Alpha's 2023 stock market prediction contest-- beating out a field of 40 analysts by correctly forecasting the S&P 500's 24% gain that year. https://seekingalpha.com/article/4660791-2023-market-prediction-contest-winners

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in BMRA over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About BMRA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BMRA

Related Stocks

SymbolLast Price% Chg
BMRA
--